Akari Therapeutics Plc ADR(AKTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -17.25 | Insider Own | 0.4% | Shs Outstand | 1.8M | Perf Week | 4.24% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 78.16% | Insider Trans | - | Shs Float | 1.7M | Perf Month | 57.38% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -2.09 | Inst Own | 8.61% | Short Float | 1.73% | Perf Quarter | -23.75% |
| Income | -0.03B | P/S | - | EPS this Y | 48.4% | Inst Trans | 239.56% | Short Ratio | 0.39 | Perf Half Y | 10.05% |
| Sales | 0.00B | P/B | 1.06 | EPS next 5Y | 46.65% | ROA | -69.02% | Short Interest | 0.03M | Perf YTD | -2.25% |
| Book/sh | 10.62 | P/C | 2.55 | EPS past 3/5Y | - | ROE | -139.8% | 52W High | -77.22% ($49.60) | Perf Year | -63.31% |
| Cash/sh | 4.43 | P/FCF | - | Sales past 3/5Y | - | ROIC | -166.16% | 52W Low | 274.79% ($3.02) | Perf 3Y | -91.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 15.5% 12.9% | Perf 5Y | -99.22% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.22 | Perf 10Y | -99.83% |
| Dividend Ex-Date | - | Quick Ratio | 0.6 | EPS Q/Q | 1.39% | Profit Margin | - | RSI (14) | 63.1 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.6 | Sales Q/Q | - | SMA20 | 20.46% ($9.38) | Beta | 1.41 | Target Price | $28.5 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/13 | SMA50 | 16.98% ($9.66) | Rel Volume | 1.74 | Prev Close | $10.88 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 100% - | SMA200 | 16% ($9.74) | Avg Volume(3M) | 0.08M | Price | $11.3 |
| IPO | 2013/5/7 | Option/Short | Yes/Yes | Trades | 1239 | Volume | 133,269 | Change | 3.86% |
Company
AKTX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A clinical-stage oncology biotech developing next-generation antibody-drug conjugates (ADCs). Its lead candidate, AKTX-101, is a Trop2-targeted ADC built on a proprietary PH1 spliceosome-inhibiting payload and features a mechanism of action that differentiates it from existing ADCs.
Over the past 1 year, on the lower side
77% below its 1-year high.
AKTX has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.4% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -92.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 8.6%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $20M.
AKTX $20M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is AKTX?
AKTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AKTX?
The market cap of AKTX is approximately $20M, ranking 5,287 within its sector.
What is the 52-week high and low for AKTX?
AKTX has recorded a 52-week high of $49.60 and a low of $3.02.
